50 institutions hold shares in Baudax Bio Inc. (BXRX), with 361.23k shares held by insiders accounting for 0.51% while institutional investors hold 19.06% of the company’s shares. The shares outstanding are 70.14M, and float is at 64.63M with Short Float at 4.69%. Institutions hold 18.96% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is North Run Capital LP with over 1.01 million shares valued at $2.8 million. The investor’s holdings represent 2.63% of the BXRX Shares outstanding. As of Sep 29, 2020, the second largest holder is Corsair Capital Management, L.P. with 0.43 million shares valued at $1.2 million to account for 1.13% of the shares outstanding. The other top investors are Renaissance Technologies, LLC which holds 0.42 million shares representing 1.10% and valued at over $0.43 million, while Vanguard Group, Inc. (The) holds 0.99% of the shares totaling 0.38 million with a market value of $1.06 million.
Baudax Bio Inc. (NASDAQ: BXRX) is 66.34% higher on its value in year-to-date trading and has touched a low of $0.97 and a high of $10.14 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BXRX stock was last observed hovering at around $1.59 in the last trading session, with the day’s gains setting it 0.09% off its average median price target of $5.00 for the next 12 months. It is also 72.0% off the consensus price target high of $6.00 offered by 3 analysts, but current levels are 44.0% higher than the price target low of $3.00 for the same period.
Currently trading at $1.68, the stock is 5.46% and 27.19% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.81 million and changing 5.66% at the moment leaves the stock -33.26% off its SMA200. BXRX registered -79.00% loss for a year compared to 6-month loss of -42.27%. The firm has a 50-day simple moving average (SMA 50) of $1.4776 and a 200-day simple moving average (SMA200) of $1.9254.
The stock witnessed a -1.18% gain in the last 1 month and extending the period to 3 months gives it a 42.37%, and is -9.68% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.51% over the week and 12.95% over the month.
Baudax Bio Inc. (BXRX) has around 57 employees, a market worth around $111.50M and $0.50M in sales. Distance from 52-week low is 73.20% and -83.43% from its 52-week high. The company has generated returns on investments over the last 12 months (1335.50%).
Baudax Bio Inc. (BXRX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Baudax Bio Inc. (BXRX) is a “Buy”. 3 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Baudax Bio Inc. is expected to release its quarterly report on 05/07/2021 and quarterly earnings per share for the current quarter are estimated at -$0.19 with sales reaching $630k over the same period.The EPS is expected to shrink by -12.90% this year, but quarterly earnings will post 2,218.50% year-over-year.
Baudax Bio Inc. (BXRX) Insider Activity
A total of 6 insider transactions have happened at Baudax Bio Inc. (BXRX) in the last six months, with sales accounting for 3 and purchases happening 3 times. The most recent transaction is an insider purchase by CHURCHILL WINSTON J, the company’s Director. SEC filings show that CHURCHILL WINSTON J bought 6,500 shares of the company’s common stock on Mar 26 at a price of $2.28 per share for a total of $14820.0. Following the purchase, the insider now owns 6500.0 shares.
Baudax Bio Inc. disclosed in a document filed with the SEC on Mar 26 that CHURCHILL WINSTON J (Director) bought a total of 25,000 shares of the company’s common stock. The trade occurred on Mar 26 and was made at $2.44 per share for $61000.0. Following the transaction, the insider now directly holds 52782.0 shares of the BXRX stock.
Still, SEC filings show that on Mar 26, Weisman Wayne (Director) acquired 10,000 shares at an average price of $2.29 for $22900.0. The insider now directly holds 40,582 shares of Baudax Bio Inc. (BXRX).